Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Success for new cholesterol-lowering drug

Success for new cholesterol-lowering drug

A new, oral drug that effectively lowers cholesterol looks set for clinical approval. The latest trials of the drug have shown that it is safe when used in conjunction with widely prescribed statins.

cholesterol builds up in the walls of arteriesVictor Josan | Shutterstock

The new study, published in The New England Journal of Medicine, was the largest study to date to test the efficacy of bempedoic acid, which is yet to be approved in Europe.

The oral medication impedes the body’s ability to create cholesterol, and could be taken in conjunction with patients’ existing statins treatments, as well acting as a treatment for those unable to take statins due to adverse side effects or interactions with other medications.

Low-density lipoprotein (LDL) cholesterol, often dubbed “bad” cholesterol, is responsible for carrying cholesterol to cells. An excess of LDL accumulates on artery walls, restricting blood flow to the heart, brain, and the rest of the body.

This can lead to a number of serious health problems including atherosclerosis, coronary heart disease, heart attack, stroke, and peripheral arterial disease, and can also increase the risk of blood clots throughout the body.

We know that reducing your cholesterol levels is key to cutting the risk of heart attack and stroke, particularly if you already have established heart disease.

Our latest study shows that bempedoic acid could be another addition to the arsenal of cholesterol-lowering treatments available to patients.

What we have is a new class of drug that could be given to patients who are already taking statins and could help them to further reduce their cholesterol levels and thus potentially cut their risk of heart attacks and strokes.”

Professor Kausik Ray, Lead Author

Statins are routinely prescribed to help to lower cholesterol in patients who are at high risk of complications caused by high cholesterol, including those with diabetes, hereditary conditions, and patients who have had a previous heart attack or stroke.

Although bempedoic acid works in a similar way to statins by blocking a cholesterol-producing enzyme ATP-citrate lyase, it boasts some advantages over commonly used statins.

“One of the key advantages of bempedoic acid is supposed to be that it shouldn’t cause the muscle side effects reported by some statins users, as it is taken up by the liver and needs to be converted into its active form via an enzyme only found in the liver,” Ray elucidates.

The study involved 2230 patients, 1488 of whom were given bempedoic acid and 742 a placebo. The patients came from a range of countries, from the UK and Germany to Poland, Canada, and the US.

Along with patients on varying intensities of cholesterol-lowering treatments, patients with familial hypercholesterolemia were also included. Hypercholesterolemia is a hereditary condition that results in increased cholesterol levels and consequent elevated risk of cardiovascular diseases and strokes.

During the 52-week trial, bempedoic acid added to “maximally tolerated statin therapy did not lead to a high incidence of overall adverse events […] and led to significantly lower LDL cholesterol levels.”

After three months, bempedoic acid had reduced LDL cholesterol levels by an average of 18.1% when compared with the placebo group. The intensity of the patients’ existing treatment plans did not affect the efficacy of bempedoic acid.

However, incidence rates of gout within the test group did see a small increase due to slightly higher levels of uric acid in the blood. Incidence of serious health conditions was not reported in either group.

A second study published by The New England Journal of Medicine used data from 654,783 people to investigate the long-term effects of bempedoic acid.

The study tracked genetic markers to determine the potential effects of inhibiting the ATP-citrate lyase enzyme with bempedoic acid. It was then compared with the enzyme that statins usually inhibit, 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR).

The study concluded that its results “strongly [imply] that inhibiting ATP-citrate lyase reduces plasma LDL cholesterol levels in the same way that inhibiting HMGCR with a statin reduces LDL cholesterol levels.”

Bempedoic acid was deemed to be potentially equally safe and effective as statins, and that it could also avoid some of the negative muscle-related side effects experienced with statins, as the new medication operates through a different mechanism of action.

“Once converted to the active form [bempedoic acid] cannot leave the liver, so it can’t enter muscles and hence could be of considerable advantage for some,” Ray explains.

Overall, these latest studies show that not only is the treatment generally well-tolerated being comparable with placebo, and potentially safe over longer periods, but that when added to high intensity statin treatment it can help to further reduce LDL cholesterol levels.

The ongoing trial, called ‘CLEAR OUTCOMES’, is specially testing even longer-term safety and whether this approach reduces cardiovascular disease in addition to lowering cholesterol.”

Professor Kausik Ray, Lead Author

Esperion, the US pharmaceutical company that is behind the new drug, is working towards gaining a license to sell the drug in both Europe and the US in 2019. However, there is no certainty that bempedoic acid would be available for patients worldwide within this timeframe.

Sources:

Mendelian Randomization Study of ACLY and Cardiovascular Disease. NEJM. 14th March 2019.

Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. NEJM. 14th March 2019.

Tagged with:

About author

Related Articles